All In Biotech

Drug Trial Radar · NCT01897896

Alternatives for Reducing Chorea in Huntington Disease

An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Nov 12, 2013

Primary completion

Aug 21, 2017

Study completion Aug 21, 2017

Sponsor

Lead sponsor
Auspex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 12, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER.

Conditions

  • Chorea Associated With Huntington Disease

Interventions

  • SD-809Drug

    SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire Treatment PeriodTime frame: Baseline to follow-up visit (up to approximately 3 years 9 months)
  2. Rollover Cohort: Number of Participants With TEAEs, Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During TitrationTime frame: Day 1 to end of Week 8
  3. Switch Cohort: Number of Participants With TEAEs, Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Dose AdjustmentTime frame: Day 1 to end of Week 4
  4. Number of Participants With TEAEs, Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Long Term Stable Dose TreatmentTime frame: Week 8 to follow-up visit (up to approximately 3 years 9 months)

Locations

38 sites in 3 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 057

    Birmingham, Alabama

  • Teva Investigational Site 038

    Phoenix, Arizona

  • Teva Investigational Site 298

    Fayetteville, Arkansas

  • Teva Investigational Site 052

    Englewood, Colorado

  • Teva Investigational Site 333

    Washington D.C., District of Columbia

  • Teva Investigational Site 160

    Gainesville, Florida

  • Teva Investigational Site 014

    Miami, Florida

  • Teva Investigational Site 032

    Atlanta, Georgia

  • Teva Investigational Site 045

    Indianapolis, Indiana

  • Teva Investigational Site 024

    Iowa City, Iowa

  • Teva Investigational Site 029

    Kansas City, Kansas

  • Teva Investigational Site 083

    Wichita, Kansas

  • Teva Investigational Site 087

    Louisville, Kentucky

  • Teva Investigational Site 028

    Baltimore, Maryland

  • Teva Investigational Site 040

    Boston, Massachusetts

  • Teva Investigational Site 027

    St Louis, Missouri

  • Teva Investigational Site 194

    Las Vegas, Nevada

  • Teva Investigational Site 328

    Camden, New Jersey

  • Teva Investigational Site 026

    New Brunswick, New Jersey

  • Teva Investigational Site 037

    Albany, New York

  • Teva Investigational Site 002

    New York, New York

  • Teva Investigational Site 342

    Patchogue, New York

  • Teva Investigational Site 119

    Durham, North Carolina

  • Teva Investigational Site 089

    Cincinnati, Ohio

  • Teva Investigational Site 020

    Columbus, Ohio

  • Teva Investigational Site 093

    Toledo, Ohio

  • Teva Investigational Site 341

    Tulsa, Oklahoma

  • Teva Investigational Site 031

    Nashville, Tennessee

  • Teva Investigational Site 007

    Houston, Texas

  • Teva Investigational Site 199

    Houston, Texas

  • Teva Investigational Site 100

    Salt Lake City, Utah

  • Teva Investigational Site 137

    Burlington, Vermont

  • Teva Investigational Site 220

    Kirkland, Washington

  • Teva Investigational Site 096

    Seattle, Washington

  • Teva Investigational Site 054

    Sydney, Australia

  • Teva Investigational Site 098

    Montreal, Canada

  • Teva Investigational Site 231

    Ottawa, Canada

  • Teva Investigational Site 300

    Toronto, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.